We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensor Provides Improved Ricin Detection

By Biotechdaily staff writers
Posted on 14 Mar 2006
An improved cartridge has been produced for a ricin handheld detector that virtually eliminates false-positive results. More...


Ricin is a protein derived from the bean of the castor oil plant. It is a potent toxin that has the potential to be used as an agent of biologic warfare and as a weapon of mass destruction.

The detection system is simple, robust, and reliable and was designed for civilian and military first responders, hospital triage personnel, and Haz Mat (hazardous material) personnel. This QTL Biosensor 2000 from QTL Biosystems (Sante Fe, NM, USA) includes tests for toxins such as ricin, botulinum neurotoxin, Staphyloccocal enterotoxin B, pathogens such as anthrax spores, and other threatening agents.

The QTL technology is relatively sensitive, fast, simple, and easy to use, with low rates of false-positives and false-negatives. The QTL Biosensor was developed and tested in conjunction with the U.S. Army Edgewood Chemical Biological Command (Washington, DC, USA) to validate its performance specifications. It has also been rigorously tested by third party agencies to validate its performance. Richard Troiano, CEO of QTL Biosystems, noted, "The QTL Biosensor provides a reliable ‘Yes' or ‘No' answer to a field responder in less than five minutes without the risk of the high degree of false-positives seen in lateral flow assays.”

QTL Biosystems produces enzyme activity and protein binding assays for the pharmaceutical and life sciences markets, and Biosensor Systems for first responders, medical triage personnel, and military users. Bioassay products have been developed for the detection of viruses, toxins, bacteria, proteins, hormones, nucleic acids, and other biologic compounds. The company's novel technologies integrate its expertise in chemistry, molecular and cell biology, and instrumentation.



Related Links:
QTL Biosystems

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Steam Sterilizer
Hi Vac II Line
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.